Australia’s CSL to cut 15% of staff and spin off vaccine division, citing challenges. $700m-$770m restructuring cost in 2026. Savings of $500m-$550m over three years to fund “high priority opportunities”. CSL supplies 130 million flu vaccine doses annually. Spin-off to create new publicly listed company in early 2026.

CSL plans to buy back $486.50m of shares this year. Net profit up 15% to $3bn. Shares drop 9.5% after restructuring announcement. Headcount reduction and vaccine spinoff affect stock price. CEO confident in strategic initiatives amid tariff concerns. Global pharma industry sees trend of share buybacks.

CSL’s strategic initiatives unaffected by tariffs. Company maintains heavy US manufacturing presence. Big pharma CEOs downplay tariff impact. Real-time data and analysis available for navigating tariff landscape. GlobalData offers Strategic Intelligence demo for market insights.

Read more at Yahoo Finance: CSL slashes 15% of workforce and offshoots vaccine division